Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.
Also called NCT06478186
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 120 participants
- Registry
-
NCT06478186
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT06478186. Randomized; triple masking; primary purpose treatment. Start 2024-08-16 (actual); primary completion 2026-12-16 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes
- Condition
- Osteoarthritis, Knee
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- triamcinolone acetonide extended-release injectable suspension; TCA-ER
- Intervention (Drug)
- Triamcinolone Acetonide- Immediate Release;TCA-IR
- Lead sponsor
- University of Kansas Medical Center
Record details
- Record id
cardio:ct-nct06478186- Content hash
ca2db85a050e5717c3cad40172d7ba9fe0f9703d51dcf4687fde24852f355073